73 related articles for article (PubMed ID: 27299748)
21. Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients.
Zhou C; Ren S; Zhou S; Zhang L; Su C; Zhang Z; Deng Q; Zhang J
Jpn J Clin Oncol; 2010 Oct; 40(10):954-60. PubMed ID: 20462983
[TBL] [Abstract][Full Text] [Related]
22. Multi-loci analysis reveals the importance of genetic variations in sensitivity of platinum-based chemotherapy in non-small-cell lung cancer.
Liu L; Wu J; Zhong R; Wu C; Zou L; Yang B; Chen W; Zhu B; Duan S; Yu D; Tan W; Nie S; Lin D; Miao X
Mol Carcinog; 2013 Dec; 52(12):923-31. PubMed ID: 22821704
[TBL] [Abstract][Full Text] [Related]
23. Lack of influence of XRCC1 and XPD gene polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancers.
Yao CY; Huang XE; Li C; Shen HB; Shi MQ; Feng JF; Pan LX; Tang JH
Asian Pac J Cancer Prev; 2009; 10(5):859-64. PubMed ID: 20104979
[TBL] [Abstract][Full Text] [Related]
24. Assessment of XPD Lys751Gln and XRCC1 T-77C polymorphisms in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy.
Liu L; Yuan P; Wu C; Zhang X; Wang F; Guo H; Zhong R; Xu Y; Wu J; Yu D; Wu T; Zhang X; Nie S; Miao X; Lin D
Lung Cancer; 2011 Jul; 73(1):110-5. PubMed ID: 21129812
[TBL] [Abstract][Full Text] [Related]
25. Clinical Significance of Long Non-Coding RNA CASC8 rs10505477 Polymorphism in Lung Cancer Susceptibility, Platinum-Based Chemotherapy Response, and Toxicity.
Hu L; Chen SH; Lv QL; Sun B; Qu Q; Qin CZ; Fan L; Guo Y; Cheng L; Zhou HH
Int J Environ Res Public Health; 2016 May; 13(6):. PubMed ID: 27249003
[TBL] [Abstract][Full Text] [Related]
26. Xeroderma pigmentosum group D haplotype predicts for response, survival, and toxicity after platinum-based chemotherapy in advanced nonsmall cell lung cancer.
Booton R; Ward T; Heighway J; Taylor P; Power F; Ashcroft L; Morris J; Thatcher N
Cancer; 2006 Jun; 106(11):2421-7. PubMed ID: 16649224
[TBL] [Abstract][Full Text] [Related]
27. Clinical significance of ERCC2 haplotype-tagging single nucleotide polymorphisms in patients with unresectable non-small cell lung cancer treated with first-line platinum-based chemotherapy.
Kim SH; Lee GW; Lee MJ; Cho YJ; Jeong YY; Kim HC; Lee JD; Hwang YS; Kim IS; Lee S; Oh SY
Lung Cancer; 2012 Sep; 77(3):578-84. PubMed ID: 22608006
[TBL] [Abstract][Full Text] [Related]
28. Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer.
Giachino DF; Ghio P; Regazzoni S; Mandrile G; Novello S; Selvaggi G; Gregori D; DeMarchi M; Scagliotti GV
Clin Cancer Res; 2007 May; 13(10):2876-81. PubMed ID: 17504986
[TBL] [Abstract][Full Text] [Related]
29. Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports.
Xu TP; Shen H; Liu LX; Shu YQ
Gene; 2013 Sep; 526(2):265-74. PubMed ID: 23727606
[TBL] [Abstract][Full Text] [Related]
30. A multicenter phase II trial of S-1 combined with bevacizumab after platinum-based chemotherapy in patients with advanced non-squamous non-small cell lung cancer.
Yamada K; Ichiki M; Takahashi K; Hisamatsu Y; Takeoka H; Azuma K; Shukuya T; Nishikawa K; Tokito T; Ishii H; Hoshino T
Cancer Chemother Pharmacol; 2016 Sep; 78(3):501-7. PubMed ID: 27402398
[TBL] [Abstract][Full Text] [Related]
31. XPG polymorphisms are associated with prognosis of advanced non-small cell lung cancer treated with platinum-based doublet chemotherapy.
Zou HZ; Zhao YQ
Genet Mol Res; 2015 Jan; 14(1):500-6. PubMed ID: 25729984
[TBL] [Abstract][Full Text] [Related]
32. [Effect of polymorphisms of NF-κB and PXR on platinum-based chemotherapy for non-small cell lung cancer].
Zhou Y; Yang P; Liu Y; Wang L
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2016 Mar; 41(3):233-7. PubMed ID: 27033785
[TBL] [Abstract][Full Text] [Related]
33. XPC Lys939Gln polymorphism is associated with the decreased response to platinum based chemotherapy in advanced non-small-cell lung cancer.
Zhu XL; Sun XC; Chen BA; Sun N; Cheng HY; Li F; Zhang HM; Feng JF; Qin SK; Cheng L; Lu ZH
Chin Med J (Engl); 2010 Dec; 123(23):3427-32. PubMed ID: 22166526
[TBL] [Abstract][Full Text] [Related]
34. Survival rates and tolerability of platinum-based chemotherapy regimens for elderly patients with non-small-cell lung cancer (NSCLC).
Costa GJ; Fernandes AL; Pereira JR; Curtis JR; Santoro IL
Lung Cancer; 2006 Aug; 53(2):171-6. PubMed ID: 16757059
[TBL] [Abstract][Full Text] [Related]
35. The A/G allele of eIF3a rs3740556 predicts platinum-based chemotherapy resistance in lung cancer patients.
Xu X; Han L; Yang H; Duan L; Zhou B; Zhao Y; Qu J; Ma R; Zhou H; Liu Z
Lung Cancer; 2013 Jan; 79(1):65-72. PubMed ID: 23127338
[TBL] [Abstract][Full Text] [Related]
36. Platinum-based chemotherapy in advanced non-small-cell lung cancer: optimal number of treatment cycles.
Rossi A; Di Maio M
Expert Rev Anticancer Ther; 2016 Jun; 16(6):653-60. PubMed ID: 27010977
[TBL] [Abstract][Full Text] [Related]
37. Association of CASP7 polymorphisms and survival of patients with non-small cell lung cancer with platinum-based chemotherapy treatment.
Qian J; Gu S; Wu Q; Zhao X; Wu W; Gao Z; Zhang W; Tan X; Wang H; Wang J; Fan W; Chen H; Han B; Lu D; Wei Q; Jin L
Chest; 2012 Sep; 142(3):680-689. PubMed ID: 22441531
[TBL] [Abstract][Full Text] [Related]
38. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer.
Kalikaki A; Kanaki M; Vassalou H; Souglakos J; Voutsina A; Georgoulias V; Mavroudis D
Clin Lung Cancer; 2009 Mar; 10(2):118-23. PubMed ID: 19362955
[TBL] [Abstract][Full Text] [Related]
39. Prediction of copper transport protein 1 (CTR1) genotype on severe cisplatin induced toxicity in non-small cell lung cancer (NSCLC) patients.
Xu X; Ren H; Zhou B; Zhao Y; Yuan R; Ma R; Zhou H; Liu Z
Lung Cancer; 2012 Aug; 77(2):438-42. PubMed ID: 22516052
[TBL] [Abstract][Full Text] [Related]
40. Predictive value of STMN1 gene promoter polymorphism (-2166T>C) in patients with advanced NSCLC treated with the combination of platinum compounds and vinorelbine.
Mlak R; Krawczyk P; Ciesielka M; Homa I; Powrózek T; Prendecka M; Kozioł P; Milanowski J; Małecka-Massalska T
Cancer Chemother Pharmacol; 2015 Sep; 76(3):621-9. PubMed ID: 26220844
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
